These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

487 related items for PubMed ID: 8144942

  • 21. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
    Gendelman M, Yassai M, Tivol E, Krueger A, Gorski J, Drobyski WR.
    Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113
    [Abstract] [Full Text] [Related]

  • 22. Murine recipients of fully mismatched donor marrow are protected from lethal graft-versus-host disease by the in vivo administration of rapamycin but develop an autoimmune-like syndrome.
    Blazar BR, Taylor PA, Snover DC, Sehgal SN, Vallera DA.
    J Immunol; 1993 Nov 15; 151(10):5726-41. PubMed ID: 8228258
    [Abstract] [Full Text] [Related]

  • 23. A model of human anti-T-cell monoclonal antibody therapy in SCID mice engrafted with human peripheral blood lymphocytes.
    Tsuchida M, Brown SA, Tutt LM, Tan J, Seehafer DL, Harris JP, Xun CQ, Thompson JS.
    Clin Transplant; 1997 Oct 15; 11(5 Pt 2):522-8. PubMed ID: 9361954
    [Abstract] [Full Text] [Related]

  • 24. Blockade of CD40 ligand-CD40 interaction impairs CD4+ T cell-mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation.
    Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Buhlman J, Xu J, Flavell RA, Korngold R, Noelle R, Vallera DA.
    J Immunol; 1997 Jan 01; 158(1):29-39. PubMed ID: 8977172
    [Abstract] [Full Text] [Related]

  • 25. Effects of in vivo administration of anti-CD3 monoclonal antibody on T cell function in mice. II. In vivo activation of T cells.
    Hirsch R, Gress RE, Pluznik DH, Eckhaus M, Bluestone JA.
    J Immunol; 1989 Feb 01; 142(3):737-43. PubMed ID: 2521507
    [Abstract] [Full Text] [Related]

  • 26. Reactivity of hybridomas derived from T cells activated in vivo during graft-versus-host disease.
    Leibnitz RR, Lipsky PE, Thiele DL.
    J Immunol; 1994 Dec 01; 153(11):4959-68. PubMed ID: 7963559
    [Abstract] [Full Text] [Related]

  • 27. Differential T cell hyporesponsiveness induced by in vivo administration of intact or F(ab')2 fragments of anti-CD3 monoclonal antibody. F(ab')2 fragments induce a selective T helper dysfunction.
    Hirsch R, Archibald J, Gress RE.
    J Immunol; 1991 Oct 01; 147(7):2088-93. PubMed ID: 1833451
    [Abstract] [Full Text] [Related]

  • 28. Modulation of antigen-specific T cell response by a non-mitogenic anti-CD3 antibody.
    Li J, Davis J, Bracht M, Carton J, Armstrong J, Gao W, Scallon B, Fung R, Emmell E, Zimmerman M, Griswold DE, Li L.
    Int Immunopharmacol; 2006 Jun 01; 6(6):880-91. PubMed ID: 16644473
    [Abstract] [Full Text] [Related]

  • 29. A CD8 DE loop peptide analog prevents graft-versus-host disease in a multiple minor histocompatibility antigen-mismatched bone marrow transplantation model.
    Choksi S, Kim JC, Whitaker-Menezes D, Murphy GF, Friedman TM, Korngold R.
    Biol Blood Marrow Transplant; 2004 Oct 01; 10(10):669-80. PubMed ID: 15389433
    [Abstract] [Full Text] [Related]

  • 30. Specific donor Vbeta-associated CD4 T-cell responses correlate with severe acute graft-versus-host disease directed to multiple minor histocompatibility antigens.
    Jones SC, Friedman TM, Murphy GF, Korngold R.
    Biol Blood Marrow Transplant; 2004 Feb 01; 10(2):91-105. PubMed ID: 14750075
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Proliferative capacity of senescent lymphocytes. II. Monoclonal antibody stimulation of mucosal and systemic lymphocytes via T cell activation molecules, CD3 epsilon, T cell receptor V beta 8 chain, and phosphatidylinositol-linked anchored receptors THY-1 and LY-6A.2/TAP.
    Green-Johnson JM, Szewczuk MR.
    Reg Immunol; 2004 Feb 01; 3(6):323-35. PubMed ID: 1983438
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Inhibition of allograft rejection by anti-T-cell receptor-alpha beta monoclonal antibodies preserving resistance to bacterial infection.
    Eto M, Yoshikai Y, Nishimura Y, Hiromatsu K, Maeda T, Nomoto K, Kong YY, Kubo RT, Kumazawa J, Nomoto K.
    Immunology; 1994 Feb 01; 81(2):198-204. PubMed ID: 8157269
    [Abstract] [Full Text] [Related]

  • 38. Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion.
    Keever-Taylor CA, Bredeson C, Loberiza FR, Casper JT, Lawton C, Rizzo D, Burns WH, Margolis DA, Vesole DH, Horowitz M, Zhang MJ, Juckett M, Drobyski WR.
    Biol Blood Marrow Transplant; 2001 Feb 01; 7(11):620-30. PubMed ID: 11760150
    [Abstract] [Full Text] [Related]

  • 39. Anti-IL-4 antibody prevents graft-versus-host disease in mice after bone marrow transplantation. The IgE allotype is an important marker of graft-versus-host disease.
    Ushiyama C, Hirano T, Miyajima H, Okumura K, Ovary Z, Hashimoto H.
    J Immunol; 1995 Mar 15; 154(6):2687-96. PubMed ID: 7876541
    [Abstract] [Full Text] [Related]

  • 40. Lethal graft-versus-host disease in mice directed to multiple minor histocompatibility antigens: features of CD8+ and CD4+ T cell responses.
    Korngold R.
    Bone Marrow Transplant; 1992 May 15; 9(5):355-64. PubMed ID: 1352163
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.